Tarceva May Improve Survival From Lung Cancer
Patients whose advanced lung cancers bear the EGFR mutation survive 2 to 3 times longer if given initial treatment with Tarceva.
Click here to read the full story.
The content has been reported and it will be reviewed by a moderator.
